Association between Serum Levels of Interleukin-25/Thymic Stromal Lymphopoietin and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease

Th2 inflammation is associated with various characteristics of patients with chronic obstructive pulmonary disease (COPD). In this study, we analyzed the COPD exacerbation risk associated with serum levels of interleukin (IL)-25/thymic stromal lymphopoietin (TSLP) and eosinophils. We studied the KOCOSS cohort, a multicenter COPD cohort created by 54 medical centers in South Korea. We extracted data collected between April 2012 and August 2020. We measured serum levels of TSLP and IL-25 in those who agreed to provide blood, and assessed exacerbation risk according to each. In all, 562 patients were enrolled. The IL-25-high group had a lower St. George’s Respiratory Questionnaire score than others, and the TSLP-high group had a poorer exercise capacity than the TSLP-low group. There were no significant differences in the forced expiratory volume in 1 s (FEV1), the levels of Th2 inflammatory biomarkers, or the exacerbation histories between the two groups. The 3-year decline in FEV1 was not significantly affected by IL-25 or TSLP levels. In terms of 1-year exacerbation risk, individuals in the IL-25-high group were at lower risk for moderate-to-severe exacerbation than others. A high TSLP level was associated with a lower risk of severe exacerbation but only in the eosinophil-low group. Serum levels of IL-25 are negatively correlated with moderate-to-severe exacerbation risk in this cohort. A negative correlation between severe exacerbation risk and TSLP level was apparent only in the eosinophil-low group.

[1]  J. Moon,et al.  Longitudinal changes in forced expiratory volume in 1 s in patients with eosinophilic chronic obstructive pulmonary disease , 2022, BMC Pulmonary Medicine.

[2]  C. Brightling,et al.  Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. , 2022, The Lancet. Respiratory medicine.

[3]  G. Koppelman,et al.  Biologic Therapies for Severe Asthma. , 2022, The New England journal of medicine.

[4]  Jian Liu,et al.  Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis , 2021, Frontiers in Pharmacology.

[5]  M. K. Ruddy,et al.  Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. , 2021, The Lancet. Respiratory medicine.

[6]  F. Maltais,et al.  Update on Asthma–COPD Overlap (ACO): A Narrative Review , 2021, International journal of chronic obstructive pulmonary disease.

[7]  I. Pavord,et al.  Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO , 2021, International journal of chronic obstructive pulmonary disease.

[8]  E. Israel,et al.  Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. , 2021, The New England journal of medicine.

[9]  S. Park,et al.  Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease , 2021, BMC Pulmonary Medicine.

[10]  J. Guiot,et al.  Sputum IL-25, IL-33 and TSLP, IL-23 and IL-36 in airway obstructive diseases. Reduced levels of IL-36 in eosinophilic phenotype. , 2021, Cytokine.

[11]  L. Koenderman,et al.  Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait , 2020, Thorax.

[12]  S. Hiles,et al.  Disease burden of eosinophilic airway disease: Comparing severe asthma, COPD and asthma–COPD overlap , 2020, Respirology.

[13]  P. Kuna,et al.  IL-33 Mediated Inflammation in Chronic Respiratory Diseases—Understanding the Role of the Member of IL-1 Superfamily , 2019, Front. Immunol..

[14]  Masaki Ikeda,et al.  Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

[15]  P. Barnes Targeting cytokines to treat asthma and chronic obstructive pulmonary disease , 2018, Nature Reviews Immunology.

[16]  Yan Li,et al.  Elevated Expression of IL-33 and TSLP in the Airways of Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease , 2018, The Journal of Immunology.

[17]  I. Pavord,et al.  Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.

[18]  E. Israel,et al.  Severe and Difficult‐to‐Treat Asthma in Adults , 2017, The New England journal of medicine.

[19]  M. R. Siddiqui,et al.  Global Initiative for Chronic Obstructive Lung Disease (GOLD) , 2017 .

[20]  D. Kim,et al.  Factors associated with plasma IL-33 levels in patients with chronic obstructive pulmonary disease , 2017, International journal of chronic obstructive pulmonary disease.

[21]  M. Cazzola,et al.  The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils , 2016, BioMed research international.

[22]  B. Nordestgaard,et al.  Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. , 2016, American journal of respiratory and critical care medicine.

[23]  C. Brightling,et al.  Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease , 2016, Therapeutic advances in chronic disease.

[24]  Dave Singh,et al.  Eosinophilic inflammation in COPD: prevalence and clinical characteristics , 2014, European Respiratory Journal.

[25]  E. Noguchi,et al.  Lower FEV1 in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV1, total IgE levels, and TSLP genotypes , 2011, International journal of chronic obstructive pulmonary disease.

[26]  S. Ziegler,et al.  Sensing the outside world: TSLP regulates barrier immunity , 2010, Nature Immunology.

[27]  C. Corrigan,et al.  The Role of Thymic Stromal Lymphopoietin in Allergic Inflammation and Chronic Obstructive Pulmonary Disease , 2010, Archivum Immunologiae et Therapiae Experimentalis.

[28]  B. O'connor,et al.  Expression and Cellular Provenance of Thymic Stromal Lymphopoietin and Chemokines in Patients with Severe Asthma and Chronic Obstructive Pulmonary Disease1 , 2008, The Journal of Immunology.

[29]  D. Robinson,et al.  Thymic Stromal Lymphopoietin Expression Is Increased in Asthmatic Airways and Correlates with Expression of Th2-Attracting Chemokines and Disease Severity1 , 2005, The Journal of Immunology.

[30]  D. Postma,et al.  Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample. , 2000, Epidemiology.

[31]  Lingyun Wu,et al.  Effect of TSLP on the function of platelets and IL-25 in chronic obstructive pulmonary disease , 2019 .